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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2014, TaiwanBackground: A urinary latex test for detection of antigens from group B Streptococcus (GBS)
has been used for the diagnosis of invasive GBS disease. However, the value of routine
screening of infants with this test has not been determined.
Methods: All infants admitted to Linkou Chang-Gung Memorial Hospital (Taoyuan, Taiwan)
from January 2005 to May 2013 were screened with a urinary GBS antigen test (Wellcogen Strep
B). Medical records were retrospectively reviewed to determine the diagnostic value of this
test.
Results: A total of 14,277 infants were tested and 38 cases had confirmed diagnoses of invasive
GBS disease (34 bacteremia, 18 meningitis, 14 both), corresponding to a prevalence of 0.27%
among our admitted infants. A total of 106 infants had positive results, but only 26 had
confirmed disease. Among infants with confirmed disease, 12 had negative antigen results.
These data allowed calculation of the sensitivity (68.4%), specificity (99.4%), positive predic-
tive value (24.5%), and negative predictive value (99.9%). Adjusting for prevalence, the disease
probability of a positive test result was 23.6%, and the probability of a negative post-test result
was 0.09%. The absolute risk reduction of a negative result was very small (0.18%). Analysis of
demographic, clinical, and laboratory parameters indicated that late age of onset (7 days-
old), presence of seizure, fever, respiratory distress, leukopenia, bandemia, thrombocyto-
penia, coagulopathy, metabolic acidosis, and elevated levels of C-reactive protein (CRP) were
significantly related to the presence of a true positive test result.
Conclusion: In our study population, the positive predictive value of the GBS antigen test was
poor and the risk reduction of a negative result was weak. These results indicate that routineeonatology, Department of Pediatrics, Chang Gung Memorial Hospital, 5 Fu-Shing Street, Kwei-Shan,
.com (M.-C. Chiang).
014.03.006
Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
Routine screening of infants for GBS 481screening with this test has a limited diagnostic value. However, GBS antigen testing appears to
be useful for early detection of disease in infants with certain demographic, clinical, and lab-
oratory risk factors.
Copyright ª 2014, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Group B Streptococcus (GBS, Streptococcus agalactiae) is a
major pathogen in neonatal care units which is responsible
for many severe infections.1e3 There is increasing attention
to such infections because they are associated with unfa-
vorable complications and poor outcomes.4 Neonatal early-
onset GBS disease (from birth to 6 days old) usually mani-
fests as pneumonia or bacteremia, and late-onset GBS
disease (from age 7 days to 89 days) usually manifests as
bacteremia, osteomyelitis, septic arthritis, or meningitis.5
In a recent review of pediatric meningitis in Northern
Taiwan, GBS was the leading pathogen for infants <1 month
old.6 Recent research estimated the case-mortality ratio as
4.4% for early-onset disease and 3.3% for late-onset dis-
ease.7 Considering the serious nature of this disease, health
care institutions have implemented numerous prevention
policies. Maternal GBS screening and intrapartum antibiotic
prophylaxis led to declines in the incidence of early-onset
GBS disease to 0.25 cases per 1000 live births in the
United States in 2010.8 Despite the success of these and
other prevention strategies, neonatal GBS disease remains
a serious problem, and the incidence of late-onset GBS
disease is unchanged.3,8
A latex agglutination test for rapid identification of GBS
has been commercially available for more than 30 years.9,10
This qualitative test can be used to test samples of serum,
cerebrospinal fluid (CSF), or urine for the presence of GBS
antigens. Urine is the most commonly used sample because
it can be easily and noninvasively acquired. Thus, many
hospitals and referral centers in Taiwan routinely use a
urinary GBS antigen test to screen infants upon admission
(personal communication: Kai-Hsiang Hsu, 2014). However,
the diagnostic value of routine urinary GBS antigen testing
of neonates has been questioned.11e14
The purpose of the present study is to test the diagnostic
value and statistical power of the urinary GBS antigen test
for routine screening of neonates upon admission, based on
retrospective analysis of patients from a single institution
in Taiwan from January 2005 to May 2013.
2. Methods
2.1. Participants
This study is a retrospective review of patients admitted to
the Neonatal Department at Linkou Chang-Gung Memorial
Hospital (Taoyuan, Taiwan) from January 2005 to May 2013.
This unit is a referral center in Northern Taiwan with 37
neonatal intensive care units (NICU) and 70 sick-babynursery beds, and an annual admission of approximately
1800 infants who are 3 months old. The hospital database
has all medical information from admission to discharge.
The Institutional Review Board of our institution approved
this study.
The database allowed analysis of the demographic and
clinical characteristics of the admitted infants. Infants with
various respiratory illnesses, including tachypnea, rapid O2
desaturation, grunting, retraction, or respiratory failure
that necessitated intubation, were considered to have
respiratory distress. Fever was defined as rectal or axillary
temperature >38C. Feeding intolerance was defined as
gastrointestinal discomfort, including decreased appetite,
frequent vomiting, large gastric residual content, or
abdominal distension. Hyperbilirubinemia was diagnosed
only if phototherapy was necessary to lower serum bilirubin
level. Seizure was diagnosed based on subtle manifesta-
tions to apparent myoclonic movement according to ob-
servations of the health care staff. Participants were
classified as having multiple clinical manifestations if all
sufficient criteria were present.
Upon admission, blood cultures, hemograms, and levels
of C-reactive protein (CRP) were determined for all infants
as part of routine sepsis workups. CSF was examined ac-
cording to the physician’s discretion if meningitis was sus-
pected. Arterial acid-base status was assessed if there were
indications of a respiratory or metabolic condition. The
following abnormalities were recorded within 24 hours of
admission: leukocytosis [white blood cell (WBC) > 30,000/
uL], leukopenia (WBC < 5000/uL), bandemia (band form
WBC > 5% of total WBC), thrombocytopenia (platelet
count < 100,000/uL), coagulopathy requiring plasma
transfusion, and metabolic acidosis indicating NaHCO3
correction. Confirmed invasive GBS disease was defined as
isolation of GBS from the blood or CSF, and it was classified
as early-onset disease if the infant was <7 days old and
late-onset disease if the infant was 7 days old.
2.2. Urinary GBS antigen test
In our institution, all infants admitted to either the NICU or
the sick-baby nursery, regardless of diagnosis, were exam-
ined for the presence of the urinary GBS antigen upon
admission as part of routine screening. All urine samples
were collected within 24 hours of admission in a sterilized
urine bag and sent for immediate testing with the Wellc-
ogen Strep B latex agglutination test (Remel, Thermo Fisher
Scientific, Lenexa, KS, USA). Standard preparation pro-
cedures, including heating, cooling, and centrifugation,
were performed according to the manufacturer’s
guidelines.
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We determined the sensitivity, specificity, positive predic-
tive value, negative predictive value, and likelihood ratio
(LR) of the urinary GBS antigen test to assess its diagnostic
value. The LR is the probability of a specific finding in pa-
tients with disease divided by the probability of the same
finding in patients without disease, an indication of diag-
nostic accuracy.15,16 Post-test odds were calculated as:
pretest odds ðprevalence=1 prevalanceÞ  LR
and post-test probability was calculated as:
post test odds=ðpost test oddsþ 1Þ:
Statistical analysis was performed with SPSS Statistics
version 20 (International Business Machines Corporation,
IBM, Armonk, New York, United States). Categorical data
were analyzed with a c2 test or Fisher’s exact test where
appropriate. Logistic regression was used to determine the
correlation of categorical dependent variables with
continuous parameters. A p value <0.05 was considered
statistically significant.
3. Results
3.1. Incidence and demography
Table 1 shows the distribution of infected infants by age at
the time of positive test results and clinical presentations.
During the 8-year study period, a total of 14,277 infants
were tested and 38 cases had confirmed invasive GBS dis-
ease (34 with bacteremia, 18 with meningitis, and 14 with
both), corresponding to a prevalence of 0.27%. Among
these 38 infants, 18 were males and 20 were females, seven
were preterm (gestational age 29e34 weeks), and six had
low birth weight (1160e2460 g). A total of 31 of the infants
were born elsewhere and transferred to our institution.
Among those inborn infants, six manifested early-onsetTable 1 Age and clinical presentation of infants who tested po
Age at positive
test result
Number of
positive
results
Clinical presentation, n
Early onset Immediately
after birth
23 Bacteremia
Meningitis
Bacteremia þ meningiti
<7 days 48 Bacteremia
Meningitis
Bacteremia þ meningiti
Late onset 7e30 days 27 Bacteremia
Meningitis
Bacteremia þ meningiti
31e89 days 8 Bacteremia
Meningitis
Bacteremia þ meningiti
Overall 106 Bacteremia
Meningitis
Bacteremia þ
meningitisdisease, which could help in estimating our institution’s
case-births ratio to be 2/3668 for 2006, 2/3852 for 2007,
and 2/4248 for 2011, and this gave to an annual incidence
of 0.5/1000 live births.
Figure 1 shows the annual occurrence of early- and late-
onset disease. There were 14 infants with early-onset dis-
ease and 24 infants with late-onset disease. More specif-
ically, three infants were diagnosed at birth, 11 were
diagnosed before they were 7 days old, 14 were diagnosed
between age 7 days and 30 days, and 10 were diagnosed
between age 31 days and 89 days. The only death was in an
early-onset infant, corresponding to amortality rate of 2.6%.
3.2. Urinary GBS antigen test
Table 2 summarizes the evaluation of the urinary GBS an-
tigen test. A total of 106 infants had positive urinary GBS
antigen tests, but only 26 had confirmed disease (true
positive results). This allowed calculation of the sensitivity
(68.4%), positive predictive value (24.5%), and false posi-
tive rate (75.5%). Among the 38 infants with confirmed
disease, 12 had negative antigen results (false negative
results); the number of true negative cases was 14,159. This
allowed calculation of the specificity (99.4%), negative
predictive value (99.9%), and false negative rate (0.08%).
The LR for a positive result was 114 and the LR for a
negative result was 0.318. Adjusting for prevalence, the
post-test probability of confirmed disease after a positive
test result was 23.5%, and the post-test probability after a
negative post-test was 0.09%. The absolute risk reduction of
disease probability of a negative result was 0.18%
(0.27e0.09%).
3.3. Risk factors
The positive predictive value of the test was low (24.5%), so
we further analyzed the risk factors associated with “true
positive” results. Table 3 summarizes demographic,sitive for the urinary group B Streptococcus (GBS) antigen.
Number of positive tests
among infected patients,
n (sensitivity)
True positive
n (%)
False positive
n (%)
3 3 (100) 3 (13) 20 (87)
1 1 (100)
s 1 1 (100)
10 7 (70) 7 (14.6) 41 (85.4)
4 4 (100)
s 3 4 (100)
12 7 (58) 9 (33) 18 (67)
7 6 (86)
s 5 4 (80)
9 5 (56) 6 (75) 2 (25)
6 5 (83)
s 5 4 (80)
34 22 (65) 26 (24.5) 80 (75.5)
18 16 (89)
14 12 (86)
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Figure 1 Number of annual cases at our institution who
tested positive in the urinary group B Streptococcus (GBS) an-
tigen test, with early-onset (black) or late-onset (gray) dis-
ease. * In 2006, 2007, and 2011, respectively, two inborn
infants were diagnosed as early-onset GBS disease. The cor-
responding case-births ratios were 2/3668 for 2006, 2/3852 for
2007, and 2/4248 for 2011 at our institution. y Universal
maternal GBS screening was adopted as a health care policy in
Taiwan in 2012. z The data of 2013 was only reviewed until May
2013, at which time there were no cases.
Routine screening of infants for GBS 483clinical, and laboratory data of infants with true and false
urinary GBS antigen test results. Sex, mode of delivery, and
gestation time (full-term or preterm) were not significantly
related to the presence of positive results. Interestingly,
75% of younger infants (age < 7 days) but only 42% of older
infants (age  7 days) had false positive results. Further
analysis indicated that late-onset infants were significantlyTable 2 Diagnostic evaluation of the urinary groupmore likely to have true positive results than early-onset
infants [p Z 0.002, odds ratio (OR) Z 4.09]. Analysis of
symptoms indicated that seizure was a powerful indicator
for GBS meningitis, and that all infants with seizures and
positive test results had confirmed GBS meningitis (no false
positives). However, only 6/18 infants (33%) with GBS
meningitis had seizures, which was compatible with a
previous pediatric study of seizure and acute phase of
bacterial meningitis.17 Infants with fever and positive test
results (p < 0.001, OR Z 9.2) and infants with respiratory
distress and positive test results (p < 0.001, ORZ 5.34) had
significantly greater probabilities of true positive test re-
sults. In otherwise healthy infants, the presence of hyper-
bilirubinemia or feeding intolerance was not significantly
related to the presence of positive results.
Numerous laboratory parameters were also important in
distinguishing true positive test results (Table 3). In partic-
ular, leukopenia (p < 0.001, OR Z 16.8) was the strongest
indicator, followed by thrombocytopenia (p Z 0.012,
OR Z 14.4), coagulopathy (p < 0.001, OR Z 7.7), elevated
CRP (p < 0.001, OR Z 7.2), metabolic acidosis (p Z 0.015,
ORZ 4.5), and bandemia (pZ 0.003, ORZ 4.2).4. Discussion
Burden of neonatal GBS disease varied across countries.18 A
previous study reported that the overall incidence of
neonatal GBS infection among live births was 0.11% in
Taiwan, and 0.17% at Linkou Chang-Gung Memorial Hospi-
tal.19 In the present study, the case-admission ratio of
culture-proven invasive GBS disease was 0.27% and case-
births ratio of early-onset disease was 0.05%. This higher
case-admission incidence may be because it includedB Streptococcus (GBS) antigen test.
Table 3 Demography, symptoms and signs, and laboratory parameters of infants with true- and false-positive results in the
urinary group B Streptococcus (GBS) antigen test.
True positive (26) n (%) False positive (80) n (%) p Odds ratio (95% CI)
Demography
Sex, male 9 (35) 42 (53) 0.113 N.S.
Method of delivery, VD 18 (69) 60 (75) 0.562 N.S.
Term (37 wk) 20 (77) 48 (60) 0.118 N.S.
Symptoms and signs
Onset 7 days old 15 (58) 20 (25) 0.002* 4.09 (1.62e10.35)
Seizure 6 (23) 0 (0) 0.001* N
Fever 14 (54) 9 (11) 0.001* 9.20 (3.26e25.96)
Respiratory distress 12 (46) 11 (14) 0.001* 5.34 (1.98e14.6)
Hyperbilirubinemia 0 (0) 9 (11) 0.109 N.S.
Feeding intolerance 0 (0) 8 (10) 0.195 N.S.
Laboratory parameters
WBC 5000/uL 15 (58) 6 (8) 0.001* 16.8 (5.38e52.54)
WBC  30,000/uL 2 (8) 4 (5) 0.634 N.S.
Bandemia 5% 11 (42) 12 (15) 0.003* 4.2 (1.54e11.19)
Platelets < 100,000/uL 4 (15) 1 (1) 0.012* 14.4 (1.53e135.15)
Coagulopathy 10 (38) 6 (8) 0.001* 7.7 (2.45e24.28)
Metabolic acidosis 6 (23) 5 (6) 0.015* 4.5 (1.25e16.27)
CRP  10 mg/L 18 (69) 19 (24) 0.001* 7.2 (2.71e19.23)
CI Z confidence interval; CRP Z C-reactive protein; N.S. Z nonspecific; VD Z vaginal delivery.
*p < 0.05 indicates statistical significance.
484 K.-H. Hsu et aladmitted infants as denominator, instead of births at our
institution alone. We used the Wellcogen Strep B test to
test concentrated urine samples and identify GBS disease.
The sensitivity and specificity of our urinary antigen test
were 68.4% and 99.4%, respectively. These statistics are
comparable to those of previous studies that used the same
assay kit (sensitivity of 68e88%, specificity of
99e99.5%).20,21 Thus, we have confidence in our examina-
tion procedures and the quality of our test results.
The sensitivity of the urinary GBS antigen test was 68.4%
and the positive LR was 114. However, the low positive
predictive value (24.5%) indicates that about 75% of the
positive antigen results were false positives. Thus, routine
use of this test may result in unnecessary and prolonged
hospitalizations and the administration of treatments that
are not needed. Restriction of the test in clinical practice
had been proposed.11e14 The high false positive rate may be
due to urine bag contamination from perineal or rectal
colonization.22,23 However, collection of urine by a cath-
eter or aspiration to reduce skin contamination is highly
invasive for most infants, and the results would still not be
conclusive.23 On the other hand, our low post-test positive
probability (23.5%) means that the accuracy of a positive
result was only about one-fourth. The positive predictive
value increased and the false positive rate decreased in
infants who experienced onset at an age of 7 days,
although there were no apparent differences in sensitivity
(Table 1). The higher positive predictive value among late-
onset infants may be because most were admitted for
symptoms that correlated with invasive GBS infection. By
contrast, routine urinary GBS antigen screening for younger
infants, especially immediately after birth, had the lowest
positive predictive value, so this practice appears to be
unnecessary from a clinical point of view.The specificity (99.4%) and negative predictive value
(99.9%) of the urinary GBS test were both satisfactory.
However, for a disease with low prevalence, it is also
important to consider the negative LR and the post-test
probability to assess the diagnostic value of a test. The
negative LR was 0.318, and there was a small decrease in
post-test probability.24 The post-test probability for a
negative result was 0.09%, and the absolute risk reduction
was merely 0.18%. Thus, for every 556 infants tested for the
urinary GBS antigen, only one would benefit from a nega-
tive result to exclude invasive disease. This indicates that
the value of universal screening for exclusion is very small.
However, for infants with increased risk of sepsis, the high
negative predictive value means that this test remains a
valuable adjunct for exclusion of GBS disease.14,21
Risk-based interpretation of the results of the urinary
GBS antigen test could assist in clinical decision-making.
Although sex, mode of delivery, and gestation period had
no effect on the number of true or false positive cases,
age at testing was discriminative. With a positive urinary
GBS antigen test, infants who were at least 7 days old had
a higher risk for true positive results. In the present
study, as in previous studies, fever, seizure, and respi-
ratory distress are the major symptoms associated with
invasive GBS disease.5,19 We also found that additional
laboratory abnormalities were also associated with GBS
disease (Table 3). Thus, infants with any of these cardinal
signs have an increased risk of invasive infection and
deserve more attention. In these circumstances, the uri-
nary GBS antigen test appears to be valuable because of
its large positive LR and its high negative predictive
value.
Analysis of the cost-effectiveness of the urinary GBS
antigen testing also indicates that routine screening is
Routine screening of infants for GBS 485probably unsuitable. In particular, each test (code: 12125C)
costs 90 National Health Insurance (NHI) points in Taiwan25
(approximately 76e105 Taiwan dollars26 or 2.6e3.6 US
dollars as of October 2013). Thus, during the study period,
1,284,930 NHI points were spent for 14,277 urinary GBS
antigen tests. For each specific condition, it cost 58,406 NHI
points to correctly diagnose one case of GBS bacteremia,
80,308 points for one case of GBS meningitis, and 49,420
points for one case of invasive infection. However, even
with our routine screening, 12 cases of bacteremia, two
cases of meningitis, and 12 cases of invasive infections
were missed, and there were many cases of overdiagnosis.
Because the risk of bacterial infection in asymptomatic
infants is low,27 we believe that the use of a risk-based
strategy to test suspected infants, instead of routine
screening of all infants, would increase diagnostic accuracy
and would be more cost-effective.
There were some limitations in this retrospective study.
First, only one blood or CSF sample was typically taken from
each infant, so it was inevitable that some samples simply
failed to yield growing pathogens, even for severely ill in-
fants. This may have led to an underestimation of the
sensitivity and an overestimation of the specificity. How-
ever, our use of a large sample size and a long study period
would minimize this limitation. Second, the case-births
ratio of early-onset disease may be underestimated.
Because most inborn infants left hospital before they were
3 days old and there was a lack of follow-up information in
this retrospective study, some early-onset cases may have
fallen ill later (i.e., aged between 3 days and 6 days) but
may have been missed in the current database. Third, we
failed to determine the impact of maternal GBS screening
and prophylaxis with intrapartum antibiotics on the occur-
rence of early-onset GBS disease. Although these pro-
cedures have been performed on selected women for years
in Taiwan, and they are known to effectively lower disease
occurrence,28 universal screening did not become a health
policy in Taiwan until 2012.29 In our study, the occurrence
of early-onset GBS infection per admission was 0.105% (15/
14,277), corresponding to about two cases/year. The
occurrence of early-onset GBS infections seems to have
declined since 2012 (Figure 1). However, because many
study infants were born outside of our facility, it was
difficult to calculate the occurrence based on live births, as
in previous surveillance studies. Finally, we were unable to
perform an adequate analysis of maternal risk factors.
Again, because many of the study infants were outborn, we
could not consider some important maternal conditions,
such as preterm rupture of the membrane, maternal fever,
or chorioamnionitis.30 We believe that maternal factors
may have an important impact on the clinical value of the
urinary GBS test, and these should be considered in future
studies.
In conclusion, based on statistical evidence of a poor
positive predictive value of a positive result and the weak
risk reduction of a negative result, we believe that routine
screening of neonates with the urinary GBS antigen test is
unnecessary. However, for infants with known risk factors,
a positive urinary GBS antigen test may aid in the early
detection of disease, and negative results may be useful for
exclusion of GBS disease.Conflicts of interest
There were no conflicts of interest stated by the authors.References
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